Align Technology, Inc. $ALGN Shares Sold by Stephens Inc. AR

Stephens Inc. AR reduced its holdings in Align Technology, Inc. (NASDAQ:ALGN) by 24.4% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,359 shares of the medical equipment provider’s stock after selling 762 shares during the quarter. Stephens Inc. AR’s holdings in Align Technology were worth $447,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in ALGN. Vanguard Group Inc. boosted its stake in Align Technology by 2.2% during the 1st quarter. Vanguard Group Inc. now owns 8,441,592 shares of the medical equipment provider’s stock valued at $1,341,031,000 after purchasing an additional 185,187 shares in the last quarter. Ninety One UK Ltd boosted its stake in Align Technology by 58.7% during the 1st quarter. Ninety One UK Ltd now owns 1,937,555 shares of the medical equipment provider’s stock valued at $307,800,000 after purchasing an additional 716,954 shares in the last quarter. Invesco Ltd. boosted its stake in Align Technology by 12.7% during the 1st quarter. Invesco Ltd. now owns 1,219,715 shares of the medical equipment provider’s stock valued at $193,764,000 after purchasing an additional 137,553 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Align Technology by 32.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 832,313 shares of the medical equipment provider’s stock valued at $132,221,000 after purchasing an additional 202,616 shares in the last quarter. Finally, Navera Investment Management Ltd. boosted its stake in Align Technology by 3.0% during the 2nd quarter. Navera Investment Management Ltd. now owns 787,559 shares of the medical equipment provider’s stock valued at $149,126,000 after purchasing an additional 23,080 shares in the last quarter. 88.43% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on ALGN. Leerink Partners decreased their price target on Align Technology from $188.00 to $172.00 and set an “outperform” rating for the company in a research note on Tuesday, October 14th. Wells Fargo & Company decreased their price target on Align Technology from $246.00 to $199.00 and set an “overweight” rating for the company in a research note on Thursday, July 31st. Stifel Nicolaus reduced their price objective on Align Technology from $275.00 to $200.00 and set a “buy” rating for the company in a research note on Thursday, July 31st. Morgan Stanley decreased their target price on Align Technology from $154.00 to $142.00 and set an “equal weight” rating on the stock in a report on Tuesday, October 21st. Finally, UBS Group decreased their target price on Align Technology from $160.00 to $155.00 and set a “neutral” rating on the stock in a report on Thursday, October 16th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Align Technology has a consensus rating of “Hold” and an average target price of $173.09.

Insider Activity at Align Technology

In other Align Technology news, CEO Joseph M. Hogan bought 7,576 shares of the firm’s stock in a transaction dated Friday, August 1st. The stock was acquired at an average price of $131.49 per share, with a total value of $996,168.24. Following the completion of the transaction, the chief executive officer directly owned 184,945 shares in the company, valued at approximately $24,318,418.05. This represents a 4.27% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.66% of the stock is currently owned by company insiders.

Align Technology Stock Down 0.6%

Shares of Align Technology stock opened at $135.21 on Friday. The stock has a market cap of $9.80 billion, a PE ratio of 22.80, a price-to-earnings-growth ratio of 1.53 and a beta of 1.70. The business has a fifty day simple moving average of $134.14 and a 200-day simple moving average of $162.80. Align Technology, Inc. has a 12 month low of $122.00 and a 12 month high of $246.19.

Align Technology (NASDAQ:ALGN) last issued its earnings results on Wednesday, July 30th. The medical equipment provider reported $2.49 EPS for the quarter, missing the consensus estimate of $2.57 by ($0.08). The business had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1.06 billion. Align Technology had a return on equity of 13.36% and a net margin of 11.04%.The business’s quarterly revenue was down 1.6% on a year-over-year basis. During the same period last year, the business earned $2.41 EPS. Align Technology has set its Q3 2025 guidance at EPS. Analysts expect that Align Technology, Inc. will post 7.98 EPS for the current fiscal year.

Align Technology announced that its board has initiated a share repurchase plan on Tuesday, August 5th that permits the company to buyback $200.00 million in shares. This buyback authorization permits the medical equipment provider to reacquire up to 2% of its shares through open market purchases. Shares buyback plans are typically an indication that the company’s management believes its shares are undervalued.

Align Technology Profile

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.